Intarcia snags $200M for yearlong diabetes minipump in PhIII; Alnylam gets orphan status positive opinion in Europe;

> Intarcia pulled in $200 million for its Phase III exenatide minipump designed to deliver the drug to diabetes patients over the course of a year. Story

> The European Medicines Agency gave Alnylam ($ALNY) a positive opinion regarding the orphan status of the company's ALN-TTRsc RNAi drug for patients with transthyretin-mediated amyloidosis. Release

> Particle Sciences entered a development agreement with Actavis ($ACT) for an unnamed generic product using one of Particle's many delivery technologies. Release

> Ablative Solutions won FDA clearance for its Peregrine infusion catheter designed to deliver drugs directly to the perivascular layer surrounding the blood vessels. Release

> Biolight filed an IND with the FDA for a Phase I/IIa study of its glaucoma implant with controlled release of latanaprost. Release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.